St. Augustine, Florida–(Newsfile Corp. – July 21, 2025) – As of Tuesday, May 20, 2025, Movora is proud to announce it has entered into an exclusivity agreement with Aesculap, a division of B. Braun VetCare, to become the sole distributor of Aesculap Surgical Power Systems and power accessories in the United States and Canada.
This partnership further strengthens Movora’s commitment to providing premium orthopedic and surgical solutions to veterinary professionals across North America. By securing exclusive distribution rights, Movora will ensure enhanced access to Aesculap’s innovative power systems, reinforcing its role as a leader in the veterinary surgical space.
“Movora has a long-standing relationship with Aesculap Surgical Power products as part of our core orthopedic business, and we are very excited about the exclusive partnership in North America, our largest market,” said Guy Spörri, CEO of Movora. “This agreement represents a significant step forward in our mission to support veterinary professionals with world-class surgical technologies.”
Achim Ott, Export Sales Manager at Aesculap/B. Braun VetCare, added: “We are very much looking forward to our continued cooperation and hope for further successful business together.”
The agreement officially designates Movora as the exclusive North American distributor of Aesculap Surgical Power and accessories, ensuring streamlined service, consistent availability, and expert support for customers across the U.S. and Canada.
Non-Movora Aesculap Power Customers will utilize Movora for all Aesculap Power Equipment Repairs moving forward. Please visit https://news.movora.com/power-repair for more information and to get started.
For more information, visit www.movora.com.
Media Contacts:
Korrie Wilhelm, VP Global MarCom, Brand Strategy & Ecommerce
Movora
Korrie.wilhelm@movora.com
904.436.6540
Achim Ott, Export Sales Manager
BBraun VetCare/Aesculap
achim.ott@aesculap.de
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258653
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…